Full-Time

Associate Director

Global Regulatory Strategy, Oncology

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

No salary listed

Senior, Expert

Cambridge, MA, USA + 1 more

More locations: Princeton, NJ, USA

70% in-office structure; hybrid work model

Category
Legal
Risk & Compliance
Legal & Compliance
Requirements
  • BA/BS degree in a scientific/engineering/healthcare discipline required
  • Masters, PharmD or PhD preferred
  • 7+ years of experience in the Pharmaceutical industry preferred
  • 5+ years of experience in Regulatory strategy or relevant training/experience preferred
  • Experience in oncology therapeutics highly preferred
  • Strong knowledge of current US regulations and knowledge of ex-US regulations
  • Strong experience with CTD format and content of regulatory filings
  • Exceptional written and oral communication
  • Knowledge of and broad experience with regulatory procedures and legislation for drug development, product registration, line extension and license maintenance at least in the US
  • Demonstrate strong organizational skills, including the ability to prioritize workload
  • Experience in developing regulatory strategies at various drug development time points
  • Experience and knowledge in the preparation of regulatory submissions and supportive amendments or supplements
  • Experience in authoring regulatory documents
  • Knowledge and understanding of applicable regulations
  • Experience working on products across all stages of product development.
Responsibilities
  • Serve as the global regulatory lead delegate for development compounds in the oncology portfolio, responsible for setting global regulatory strategy with the GRL, representing regulatory on the development core teams, and leading the Global Regulatory Sub-teams with support from the GRL
  • Sets strategic direction for the US market, in collaboration and alignment with the global product strategy with GRL, Global Regulatory Sub-Teams and project teams for assigned programs
  • Ensures the US regulatory strategy is aligned with the global strategy for assigned programs, including for investigational new drug application submissions
  • Leads the strategy for US FDA interactions with the cross functional team, including development of content, format and accountability for regulatory submissions and related supplements and amendments, FDA meeting requests, briefing books, INDs, CTAs, orphan drug designations, pediatric plans, DSURs, etc.
  • Conducts risk assessment and identifies potential areas of regulatory concern for assigned projects or programs and responds to emerging health authority regulations and requirements
  • In collaboration with the cross functional team, leads the response to health authority requests for additional data, organizes and manages participation in meetings relevant to aspects of compound development
  • Reviews and may approve regulatory documents prior to submission to respective regulatory authority(ies)
  • Serves as primary point of contact and negotiates directly and effectively with FDA and other health agencies for assigned programs
  • May serve as regulatory affairs representative to provide input on clinical trials and filing activities and to ensure that report systems are maintained and compliant
  • Identify areas in need of improvement and lead the development and implementation of process improvements.
Desired Qualifications
  • 7+ years of experience in the Pharmaceutical industry preferred
  • 5+ years of experience in Regulatory strategy or relevant training/experience preferred
  • Experience in oncology therapeutics highly preferred

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their products work by delivering mRNA into the body, which instructs cells to create specific proteins that can help prevent or treat diseases. This approach is different from traditional medicines, as it allows for a more direct and potentially faster way to develop treatments. Moderna's goal is to create a new category of medicines that can significantly enhance patient care and improve health outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's RSV vaccine received approval in Australia and the UK in 2025.
  • The company is collaborating with Merck on a personalized cancer vaccine for 2027.
  • Moderna's late-stage pipeline shows strong momentum with multiple product approvals expected.

What critics are saying

  • Patent litigation with Pfizer and BioNTech could impact Moderna's financials.
  • HHS review of bird flu vaccine contract may affect revenue projections.
  • Moderna reported a significant net loss in 2024, affecting investor confidence.

What makes Moderna unique

  • Moderna is pioneering mRNA technology as a new class of medicines.
  • mRNA technology allows for rapid development and manufacturing of vaccines.
  • Moderna's mRNA platform is versatile, targeting infectious and non-infectious diseases.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

5%
Notas de Prensa
Apr 7th, 2025
Moderna to showcase its extensive research on Infectious Diseases at ESCMID 2025.

Moderna, Inc. (NASDAQ:MRNA) announces that it will present at the World Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), which will be held in Vienna, Austria, from April 11 to 15, 2025, its research in multiple areas of infectious diseases, such as COVID-19, influenza, respiratory syncytial virus, cytomegalovirus, norovirus, and mpox.

PharmiWeb
Mar 31st, 2025
Moderna Receives Australian Therapeutic Goods Administration Approval For Rsv Vaccine For Older Adults

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.1 mRESVIA's approval marks a significant milestone as it is the first mRNA vaccine in Australia approved for use against a disease beyond COVID-19."We are pleased to receive regulatory approval for mRESVIA in Australia following the TGA's decision," said Stéphane Bancel, Chief Executive Officer of Moderna. "This approval underscores our commitment to protecting older adults from RSV-related respiratory diseases. We look forward to supplying mRESVIA from our Melbourne facility to older Australians vulnerable to RSV in the future."RSV is a highly contagious respiratory virus that causes a substantial burden of disease, particularly in older adults. In the 2024 Australian winter period, RSV laboratory-notified cases in adults aged 65 and older were nearly two-thirds the number of influenza cases in the same age group.2 90% of RSV-related deaths reported nationally occurred in those aged 60 years and older, underscoring its potential for severe impact on older Australians.2The approval is based on positive data from the Phase 3 clinical trial ConquerRSV, a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults aged 60 years or older in 22 countries.About mRESVIA (Respiratory Syncytial Virus Vaccine)mRNA-1345 is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells

PharmiWeb
Mar 28th, 2025
Moderna Receives Medicines And Healthcare Products Regulatory Agency Marketing Authorization In The Uk For Rsv Vaccine

mRESVIA® is Moderna's second approved product in the UKCAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older."The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our RSV vaccine will be manufactured at the Moderna Innovation and Technology Centre in Oxfordshire, which will be fully operational later this year."RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia. In the UK, RSV has an impact on elderly adults and is responsible for 175,000 GP appointments, 14,000 hospitalizations, and 8,000 deaths in adults 65 years of age and older per year.[i]"Given the serious consequences of RSV for older people, which can lead to hospitalization and severe outcomes, we are delighted that the MHRA has authorized our RSV vaccine," said Darius Hughes, UK General Manager of Moderna. "With the MHRA decision, mRESVIA becomes Moderna's second approved product in the UK, further demonstrating the role of mRNA vaccines in helping to protect the public from respiratory diseases."The approval is based on positive data from the Phase 3 clinical trial ConquerRSV , a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults aged 60 years or older in 22 countries. No serious safety concerns were identified in the Phase 3 trial.About mRNA-1345 (Respiratory Syncytial Virus Vaccine)mRNA-1345 is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein

Bioversity International
Mar 27th, 2025
Bioversity and the Massachusetts College of Pharmacy and Health Sciences (MCPHS) Launch New Biomanufacturing Training Program in Collaboration with Moderna

Bioversity and the Massachusetts College of Pharmacy and Health Sciences (MCPHS) launch new biomanufacturing training program in collaboration with Moderna.

Assure Test
Mar 7th, 2025
Pfizer & BioNTech vs. Moderna: COVID-19 Vaccine Patent Lawsuit

The high-profile lawsuit between Pfizer, BioNTech, and Moderna over mRNA COVID-19 vaccine patents remains one of the most closely watched cases in 2025.